Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (Nasdaq: VERV) is a cutting-edge biotechnology company headquartered in Cambridge, Massachusetts. With a mission to protect the world from heart disease, Verve is pioneering a transformative approach in cardiovascular care. The company leverages two major breakthroughs in 21st-century biomedicine—human genetics analysis and gene editing—to create life-changing therapies for coronary heart disease.
Verve Therapeutics is focused on developing single-course gene editing medicines to permanently lower LDL cholesterol and triglyceride levels in adults, thereby reducing the risk of coronary heart disease. Their innovative treatments are designed to be administered once in a lifetime, offering a potential shift from chronic disease management to a one-time cure.
Founded by leading experts in cardiovascular medicine, human genetics, and gene editing, Verve has garnered substantial support from top-tier investors, including GV (formerly Google Ventures), Arch Venture Partners, and others. The company was recognized as a '2020 Best Places to Work' by the Boston Business Journal, highlighting its positive workplace culture and innovative environment.
Verve's flagship programs include VERVE-101, VERVE-102, and VERVE-201, each targeting genes validated for their role in lowering low-density lipoprotein cholesterol (LDL-C). Specifically, VERVE-101 and VERVE-102 aim to permanently deactivate the PCSK9 gene, initially targeting patients with heterozygous familial hypercholesterolemia (HeFH) and eventually expanding to treat patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C goals using traditional therapies. Meanwhile, VERVE-201 targets the ANGPTL3 gene, focusing on patients with homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia.
Recent milestones for Verve Therapeutics include the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. This study demonstrated dose-dependent reductions in disease-causing LDL-C in patients with HeFH. The company is also progressing with the heart-2 phase 1b clinical trial for VERVE-102 and plans to launch a phase 1b trial for VERVE-201 in the latter half of 2024.
In terms of financial performance, Verve maintains a solid cash position, with $624.0 million in cash and marketable securities as of December 31, 2023. This robust financial standing is augmented by strategic partnerships, including a significant collaboration with Eli Lilly, which involved a private placement and potential milestone payments up to $465 million.
Under the leadership of CEO Sekar Kathiresan, M.D., Verve is pushing the boundaries of cardiovascular disease treatment. The company's relentless commitment to scientific excellence and patient care positions it as a potential game-changer in the field of genetic medicine.
Verve Therapeutics has announced a collaboration with Vertex Pharmaceuticals, securing a $60 million upfront payment, which includes a $35 million equity investment. The partnership aims to develop an in vivo gene editing program targeting a specific liver disease over four years. Vertex will finance the research, while retaining rights to future development and commercialization. Verve could also earn up to $406 million in milestone payments and royalties on potential net sales. This collaboration marks a pivotal step in Verve's ongoing efforts to innovate gene editing therapies for cardiovascular diseases.
Verve Therapeutics announces the start of the Phase 1b clinical trial, heart-1, for its investigational gene editing medicine, VERVE-101, aimed at treating patients with heterozygous familial hypercholesterolemia (HeFH). The first patient has been dosed, marking a significant milestone in its development. VERVE-101 seeks to permanently deactivate the PCSK9 gene in the liver to reduce low-density lipoprotein cholesterol (LDL-C) levels. The trial plans to enroll around 40 participants, with interim data expected in 2023.
Verve Therapeutics has appointed Alexander G. “Bo” Cumbo, former CEO of AavantiBio, to its board of directors. Cumbo, who has over 28 years of experience in the pharmaceutical industry, brings a wealth of expertise in drug development and commercial execution. His appointment comes as Verve advances its regulatory strategy for VERVE-101 and its second program targeting ANGPTL3. The company aims to transform cardiovascular disease treatment from chronic management to single-course therapies, with VERVE-101 targeting familial hypercholesterolemia.
Verve Therapeutics will showcase its innovative approach to treating cardiovascular disease at the 2022 Jefferies Healthcare Conference. Co-founder and CEO Sekar Kathiresan will speak on June 8, 2022, at 1:00 p.m. ET in NYC. The company focuses on single-course gene editing medicines, specifically targeting PCSK9 and ANGPTL3 genes to lower LDL cholesterol levels. Verve’s lead candidate, VERVE-101, aims to reduce cardiovascular risk by permanently turning off the PCSK9 gene in the liver. A live webcast will be available on their investor website and archived for 60 days.
Verve Therapeutics has announced its strategic advancements for VERVE-101, aiming to treat heterozygous familial hypercholesterolemia (HeFH). The company has received clinical trial application clearance in New Zealand, with plans for a Phase 1 trial to start mid-2022 and initial data expected in 2023. Additionally, they are preparing regulatory submissions in the UK and US by late 2022. As of March 31, 2022, Verve holds $323.3 million in cash, providing a cash runway through 2024.
Verve Therapeutics announced significant results from its VERVE-101 program targeting heterozygous familial hypercholesterolemia (HeFH). The preclinical data revealed a mean 68% reduction in plasma LDL-C in non-human primates (NHPs) after a single intravenous infusion, with results sustained for up to one year. The administration was well-tolerated, and the GalNAc-Lipid Nanoparticle technology showed improved delivery potency, achieving a 98% reduction in blood ANGPTL3 after 15 days. Verve aims for global regulatory submissions this year to advance VERVE-101 into clinical trials.
Verve Therapeutics has announced that its CEO, Sekar Kathiresan, will participate in two significant investor conferences in May 2022. The first is the BofA Securities 2022 Healthcare Conference on May 11 at 2:40 p.m. PT in Las Vegas, followed by a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 p.m. ET in NYC. Live webcasts of both events will be accessible on the company’s website and archived for 60 days. Verve focuses on gene editing medicines to treat cardiovascular disease, with its lead product candidate, VERVE-101, targeting the PCSK9 gene to lower LDL-C levels.
Verve Therapeutics announced promising results from an off-target assessment of its lead candidate, VERVE-101, intended for treating cardiovascular disease. Whole genome sequencing showed minimal to no off-target editing in liver cells, supporting a favorable tolerability profile. VERVE-101 targets the PCSK9 gene to reduce LDL cholesterol. Verve aims to initiate clinical trials for heterozygous familial hypercholesterolemia in 2022. The findings will be presented at the Precision Genome Engineering Keystone Symposia on April 29, 2022.
Verve Therapeutics announces updated preclinical data on its base editing therapies targeting ANGPTL3 and PCSK9 genes for treating atherosclerotic cardiovascular disease (ASCVD). Data demonstrated durable and well-tolerated gene editing in non-human primates, with significant reductions in blood ANGPTL3 and PCSK9 proteins. The findings support the potential of these therapies to offer long-term LDL-C lowering solutions, particularly for patients with unmet needs. The data is being presented at the American College of Cardiology 71st Annual Scientific Session on April 4, 2022.
Verve Therapeutics, a biotechnology company focused on cardiovascular disease treatment, has announced that its Chief Scientific Officer, Dr. Andrew Bellinger, will participate in a fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on March 31, 2022, at 10:00 a.m. ET. The event will be available via a live webcast on the company's investor website and archived for 60 days. Verve is known for its innovative gene editing medicines, including its lead product candidate, VERVE-101, aimed at permanently reducing LDL cholesterol levels to mitigate cardiovascular disease risk.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is Verve Therapeutics' main focus?
Where is Verve Therapeutics headquartered?
What are the key programs of Verve Therapeutics?
Who are some of Verve Therapeutics' investors?
What recent milestone has Verve Therapeutics achieved?
What is the financial condition of Verve Therapeutics?
What is VERVE-101 designed to do?
Who is the CEO of Verve Therapeutics?
What is the significance of Verve's collaboration with Eli Lilly?
What recognition has Verve Therapeutics received?
